OCS stock forecast, quote, news & analysis
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care... Show more
Why Is Oculis Holding AG (OCS) Stock Down -35.63% Today?
Key Takeaways
- OCS shares fell sharply, declining 35.63% from the prior session close of 22.705 to the latest available price of 14.615.
- The primary catalyst was the failure of Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 in diabetic macular edema to meet the primary endpoint on visual acuity improvement.
- Secondary drivers included the company's decision to shelve plans for an FDA filing and multiple analyst price target reductions.
- Broader biotech sector volatility and elevated trading volume amplified the downside move.
- Traders are now focused on updates to the remaining pipeline in optic neuritis and dry eye disease, along with the company's cash runway into 2029.
Opening Summary
Oculis Holding AG (OCS) is a clinical-stage biopharmaceutical company developing innovative topical treatments for eye diseases. Shares plunged 35.63% in today's session after closing the previous completed trading day at 22.705. The latest available price reached 14.615 amid heavy selling pressure. Market reaction centered on disappointing late-stage trial results for the company's lead candidate and subsequent corporate and analyst responses.
Phase 3 Trial Setback
The DIAMOND-1 and DIAMOND-2 Phase 3 studies of OCS-01, an eye-drop formulation for diabetic macular edema, did not achieve the primary endpoint of meaningful improvement in visual acuity. The trials enrolled more than 800 patients and had been viewed as pivotal for potential regulatory approval and commercialization. Failure to meet this key goal triggered immediate reassessment of the program's viability.
Corporate and Analyst Response
Following the trial outcomes, Oculis indicated it would not pursue an immediate FDA filing for OCS-01 in diabetic macular edema. On the same day, several Wall Street firms lowered price targets while maintaining Buy ratings, with reductions ranging from prior levels near 45–75 down to the mid-20s to mid-40s. These actions reinforced negative sentiment and contributed to sustained selling.
Market Context and Trading Activity
Volume surged well above recent averages as investors reacted to the binary clinical outcome. The decline diverged from broader market indices, which traded relatively stable. Peers in the ophthalmology and biotech space also faced pressure, though OCS experienced outsized movement typical of clinical-stage companies facing pivotal data disappointments. Technical support levels from prior sessions were decisively broken.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. The platform features hundreds of AI-driven strategies across thousands of tickers, with selection based on backtested performance, risk metrics, and adaptability to prevailing trends. Bots differ in timeframes, asset focus, and methodologies. Explore the curated list to identify automated approaches suited to volatile names like OCS.
What Comes Next for OCS
Attention now shifts to remaining pipeline assets, including Licaminlimab for dry eye disease and Privosegtor for optic neuritis, both supported by prior regulatory designations. The company maintains a cash position sufficient to fund operations into the second half of 2029. Upcoming catalysts include potential data readouts from ongoing studies and any updates on strategic options for the OCS-01 program. Risks include further clinical setbacks, dilution, and sector-wide sentiment shifts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
OCS in -2.01% downward trend, sliding for three consecutive days on June 18, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OCS declined for three days, in of 190 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OCS as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for OCS turned negative on May 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .
OCS moved below its 50-day moving average on May 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OCS crossed bearishly below the 50-day moving average on June 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for OCS entered a downward trend on June 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 51 cases where OCS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OCS advanced for three days, in of 188 cases, the price rose further within the following month. The odds of a continued upward trend are .
OCS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.733) is normal, around the industry mean (20.059). P/E Ratio (63.076) is within average values for comparable stocks, (35.871). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). OCS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (361.315).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OCS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology